bluuebunny/crossref_metadata_2025_split huggingface dataset:
961-P: Efficacy and Safety of Once-Weekly Semaglutide vs. Once-Daily Sitagliptin as Add-On to Metformin in Subjects with Type 2 Diabetes (SUSTAIN China MRCT): A 30-Week Double-Blind, Phase 3a, Randomised Trial
Authors: JI LINONG , XIAOLIN DONG , ELIASCHEWITZ FREDDY , LI YIMING , LI YUFENG , LIM SOO , LIU MING , ZU NING , RASMUSSEN SOEREN , SKJOETH TRINE V. , YUAN GUOYUE , HUANG YU-YAO 
Published: June 2020

A total of 868 subjects of which 70% were Chinese and 13% Korean were randomised to once-weekly subcutaneous semaglutide 0.5 mg (n=288), 1.0 mg (n=290) or sitagliptin 100 mg (n=290) in a multiregional clinical trial. Both doses of semaglutide were superior to sitagliptin in reducing HbA1c (primary endpoint, Figure 1) and body weight (Table 1) after 30 weeks of treatment. The odds for achieving target HbA1c, weight loss of ≥5% or ≥10% and a composite endpoint were all significantly higher with both semaglutide doses compared to sitagliptin (Table 1). The safety profile of semaglutide was consistent with the previously established profile. Consistent efficacy and safety findings were seen in the Chinese population.

Disclosure
L. Ji: None. D. Xiaolin: None. F. Eliaschewitz: Advisory Panel; Self; AstraZeneca, Novo Nordisk A/S, Sanofi-Aventis. Research Support; Self; Bayer AG, GlaxoSmithKline plc., Novo Nordisk A/S, Sanofi-Aventis. Speaker’s Bureau; Self; Eli Lilly and Company. Y. Li: None. Y. Li: None. S. Lim: None. M. Liu: None. N. Zu: Employee; Self; Novo Nordisk A/S. S. Rasmussen: Employee; Self; Novo Nordisk A/S. T.V. Skjoeth: Employee; Self; Novo Nordisk A/S. G. Yuan: None. Y. Huang: None.

Funding
Novo Nordisk A/S
964-P: Glycemic and Body Weight Responses to Oral Semaglutide in the PIONEER Trial Program
Authors: DUNGAN KATHLEEN M. , HERTZ CHRISTIN L. , MELLBIN LINDA , NIELSEN MORTEN ABILDLUND , SØRRIG RASMUS , WOO VINCENT C. , VILSBØLL TINA 
Published: June 2020

The PIONEER phase 3 program investigated glycemic response and other efficacy endpoints in patients (pts) with type 2 diabetes randomized to the glucagon-like peptide-1 analog oral semaglutide (sema; 3, 7 or 14 mg once daily), placebo (pbo) or an active comparator (empagliflozin [empa] 25 mg, sitagliptin [sita] 100 mg or liraglutide [lira] 1.8 mg once daily). This post-hoc analysis of the PIONEER 1-5 and 8 trials evaluated the response of any reduction in HbA1c (%) and/or body weight (%), and a clinically relevant composite endpoint of HbA1c reduction ≥1% and body weight loss ≥5%, with oral sema 14 mg vs. comparators at the end of treatment (26-78 weeks). Across trials, any reduction in HbA1c was observed in higher proportions of pts with oral sema (89-95%) than with pbo (51-64%) or active comparators (82-88%). A simultaneous reduction in both HbA1c and body weight was seen in 72-86% of pts treated with oral sema (Figure). The composite of HbA1c reduction ≥1% and body weight loss ≥5% was achieved by 27-41% of pts with oral sema, 1-8% of pts with pbo, 11% with sita 100 mg, 18% with lira 1.8 mg, and 20% with empa 25 mg. Within each trial, the odds of achieving HbA1c reduction of ≥1% and body weight loss of ≥5% with oral sema 14 mg were significantly greater vs. all comparators (p&lt;0.0001). These results demonstrate that oral sema 14 mg was more effective vs. comparators for providing any HbA1c reduction, or both an HbA1c reduction ≥1% and body weight loss ≥5%.

Disclosure
K.M. Dungan: Advisory Panel; Self; Eli Lilly and Company, Elsevier. Research Support; Self; Novo Nordisk Inc., Sanofi-Aventis. Speaker’s Bureau; Self; Nova Biomedical. Other Relationship; Self; UpToDate, Vizient Inc. C.L. Hertz: Employee; Self; Novo Nordisk A/S. L. Mellbin: Advisory Panel; Self; Amgen, AstraZeneca, Novo Nordisk A/S, Sanofi-Aventis. Consultant; Self; AstraZeneca, Bayer AG, Novo Nordisk A/S. Research Support; Self; Bayer AG. Speaker’s Bureau; Self; Novo Nordisk A/S. Other Relationship; Self; Novo Nordisk Foundation. M. Abildlund Nielsen: Employee; Self; Novo Nordisk A/S. Stock/Shareholder; Self; Novo Nordisk A/S. Stock/Shareholder; Spouse/Partner; Novo Nordisk A/S. R. Sørrig: Employee; Self; Novo Nordisk A/S. V.C. Woo: Advisory Panel; Self; AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Lilly Diabetes, Novo Nordisk Inc. Speaker’s Bureau; Self; AstraZeneca, Boehringer Ingelheim (Canada) Ltd., Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Novo Nordisk Inc., Sanofi-Aventis. T. Vilsbøll: Advisory Panel; Self; AstraZeneca, Mundipharma International, Novo Nordisk A/S, Sun Pharmaceutical Industries Ltd. Consultant; Self; Boehringer Ingelheim Pharmaceuticals, Inc., Lilly Diabetes, Medscape, Merck Sharp & Dohme Corp., Sanofi.

Funding
Novo Nordisk A/S
977-P: Alleviating Carbohydrate Counting with a FiASP-and-Pramlintide Artificial Pancreas: A Randomized Pilot Study
Authors: TSOUKAS MICHAEL , PALISAITIS EMILIE , RUTKOWSKI JOANNA , VON OETTINGEN JULIA E. , LEGAULT LAURENT , YALE JEAN-FRANÇOIS , HAIDAR AHMAD 
Published: June 2020

Objective: The aim of this pilot study was to assess if a FiASP-and-pramlintide artificial pancreas (AP) could alleviate the need for CHO counting by using a simple meal announcement system (pressing a button, no CHO counting) without degrading glycemic control.
Methods: We conducted a 24-hour inpatient, randomized, crossover, non-inferiority, pilot study to compare (i) FiASP AP with full CHO counting (FCC) and CHO-matched boluses with (ii) FiASP-and-pramlintide AP with simple meal announcement (SMA). Pramlintide and FiASP were delivered in a basal-bolus manner using a fixed ratio (1U: 10µg).
Results: Seven participants (age 26.2±16, HbA1c 8.4±0.8%) were included in the analysis. The time in range (3.9-10 mmol/L) was 85.7% (IQR: [72-93]) in the FCC arm and 87.3% [75-95] in the SMA arm (p=0.21). Time spent &gt;10mmol/L did not differ between interventions (FCC: 11.4% [0.9-22], SMA: 10.1% [3.1-25], p=0.38). Time &lt;3.9mmol/L was lower in the SMA arm (2.1% vs. 4.1%, p=0.02). One participant experienced persistent GI symptoms in the SMA arm.
Conclusions: The FiASP-and-pramlintide SMA system has the potential of reducing the burden of CHO counting without degrading glucose control. Outpatient studies are warranted.

Disclosure
M. Tsoukas: Advisory Panel; Self; Eli Lilly and Company, Novo Nordisk Inc. Speaker’s Bureau; Self; Boehringer Ingelheim (Canada) Ltd., Janssen Scientific Affairs, LLC. E. Palisaitis: None. J. Rutkowski: None. J.E. von Oettingen: None. L. Legault: Advisory Panel; Self; Dexcom, Inc., Lilly Diabetes. Research Support; Self; AstraZeneca K.K., Merck & Co., Inc., Sanofi-Aventis. Other Relationship; Self; Lilly Diabetes. J. Yale: Advisory Panel; Self; AstraZeneca, Boehringer Ingelheim (Canada) Ltd., Eli Lilly and Company, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Novo Nordisk A/S, Sanofi. Board Member; Self; Diagnos. Research Support; Self; Bayer Inc., Novo Nordisk A/S, Sanofi. Speaker’s Bureau; Self; Abbott, AstraZeneca, Boehringer Ingelheim (Canada) Ltd., Eli Lilly and Company, Janssen Pharmaceuticals, Inc., Medtronic, Novo Nordisk A/S, Sanofi. A. Haidar: Consultant; Self; Eli Lilly and Company. Research Support; Self; Dexcom, Inc., Eli Lilly and Company.

Funding
JDRF (2-SRA-2018-654-M-B)
978-P: Omnipod Personalized MPC Algorithm at Target Glucose of 110mg/dl Is Safe in Adults and Adolescents without Increasing Risk of Hypoglycemia
Authors: FORLENZA GREGORY P. , BUCKINGHAM BRUCE A. , SHERR JENNIFER , WADWA R. PAUL , GALDERISI ALFONSO , EKHLASPOUR LAYA , BERGET CARI , HSU LIANA , ZGORSKI MELINDA , LEE JOON BOK , OCONNOR JASON B. , DUMAIS BONNIE , VIENNEAU TODD , HUYETT LAUREN M. , LY TRANG T. 
Published: June 2020

Customization of glucose targets in hybrid closed-loop (HCL) systems is important to enable tailored glucose management and safe onboarding across a wide range of users. The safety and performance of the Omnipod HCL personalized model predictive control (MPC) algorithm were assessed with a lower target of 110mg/dL for the first time in those aged 12-85y with type 1 diabetes (T1D) and A1C&lt;10.0% using an investigational device.
A 96-h HCL study was conducted in a supervised free-living hotel setting with challenges including 2 missed meal boluses, high fat dinner, and daily exercise. All participants used a 120mg/dL target for 48h, with either a day/night target of 150/110 mg/dL (n=10) or a constant 110mg/dL target (n=10) for the remaining 48h.
Participants (n=20) were (mean±SD): age 17.9±4.4y, T1D duration 9.0±5.4y, and A1C 7.6±0.9%. Despite 2 missed meal boluses (23-162g CHO), percent time from 70-180mg/dL was 76.1±14.9% and 72.9±9.2% with targets of 110 and 120mg/dL respectively (Table). Percent time &lt;70mg/dL was low: 2.3±2.1% and 1.9±2.5% at the respective targets.
The Omnipod personalized MPC algorithm performed well and was safe in adults and adolescents with T1D when tested at a target of 110mg/dL, even when stress-tested under challenging conditions. This algorithm is being evaluated in an at-home pivotal study with targets 110-150mg/dL.

Disclosure
G.P. Forlenza: Advisory Panel; Self; Medtronic. Consultant; Self; Dexcom, Inc., Insulet Corporation, Tandem Diabetes Care. Research Support; Self; Abbott, Dexcom, Inc., Insulet Corporation, Medtronic, Tandem Diabetes Care. B.A. Buckingham: Advisory Panel; Self; ConvaTec Inc., Medtronic. Research Support; Self; Beta Bionics, Inc., Dexcom, Inc., Insulet Corporation, Medtronic, Tandem Diabetes Care. J. Sherr: Advisory Panel; Self; Bigfoot Biomedical, Cecelia Health. Consultant; Self; Eli Lilly and Company, Lexicon Pharmaceuticals, Inc., Medtronic, Sanofi, T1D Exchange. R. Wadwa: Advisory Panel; Self; Eli Lilly and Company, Medtronic. Research Support; Self; Dexcom, Inc., Eli Lilly and Company, MannKind Corporation, Medtronic, Novo Nordisk Inc., Tandem Diabetes Care. A. Galderisi: None. L. Ekhlaspour: None. C. Berget: None. L. Hsu: Stock/Shareholder; Self; Dexcom, Inc., Insulet Corporation, Tandem Diabetes Care. M. Zgorski: None. J. Lee: Employee; Self; Insulet Corporation. J.B. OConnor: None. B. Dumais: Employee; Self; Insulet Corporation. T. Vienneau: Employee; Self; Insulet Corporation. Stock/Shareholder; Self; Insulet Corporation. L.M. Huyett: Employee; Self; Insulet Corporation. T.T. Ly: Employee; Self; Insulet Corporation.

Funding
Insulet Corporation
981-P: Postprandial Hyperglycemia following Insulin Suspensions by the Artificial Pancreas: Implications for Bolus Calculators
Authors: MAJOR SANDRINE , FATHI ANAS EL , PALISAITIS EMILIE , KEARNEY ROBERT E. , VON OETTINGEN JULIA E. , LEGAULT LAURENT , HAIDAR AHMAD 
Published: June 2020

Objective: Conventional bolus calculators apply negative prandial insulin corrections when pre-meal glucose levels are low. The present study examined the need for this negative correction with the artificial pancreas (AP).
Methods: Data were retrospectively analysed from a study conducted in a camp for children with type 1 diabetes. Meal boluses with negative corrections (n=98) of 47 participants (between 8-22 years old) using the McGill AP for 11 days were examined. The duration of insulin suspension before each meal and the insulin-on-board (IOB) at mealtime were calculated. The effects of these factors on postprandial hyperglycemia were analysed.
Results: The rate of postprandial hyperglycemia was 28% (18/65) for meals preceded by basal insulin suspensions &lt;70 minutes, and 52% (17/33) for meals preceded by suspensions ≥70 minutes (p=0.02). The rate of postprandial hyperglycemia following suspensions ≥70 minutes compared to &lt;70 minutes was significantly higher only if there was no IOB (64% [9/14] vs. 29% [13/45]; p=0.01). Meal size and total daily insulin dose did not influence these results.
Conclusion: Negative corrections with meal boluses may not be necessary following long insulin suspensions in the absence of IOB.

Disclosure
S. Major: None. A. El Fathi: None. E. Palisaitis: None. R.E. Kearney: None. J.E. von Oettingen: None. L. Legault: Advisory Panel; Self; Dexcom, Inc., Lilly Diabetes. Research Support; Self; AstraZeneca K.K., Merck & Co., Inc., Sanofi-Aventis. Other Relationship; Self; Lilly Diabetes. A. Haidar: Consultant; Self; Eli Lilly and Company. Research Support; Self; Dexcom, Inc., Eli Lilly and Company.

Funding
Canadian Institutes of Health Research (356406)
985-P: Insulin Excipient Removal Is Counterbalanced by Insulin Fibril Formation
Authors: LEWIS BRIANNE , MULKA ADAM , KESSERWAN CHAFICA , KREUTZER DON , KLUEH ULRIKE 
Published: June 2020

Objective: Insulin infusion pump sets are only FDA approved for 3 days as device failure often ensues from an inflammatory response driven by insulin excipients. However, removal of excipients can result in insulin fibril formation, which is more toxic than excipients alone. Our objective was to determine excipient and fibril toxicity and optimize the parameters of insulin excipient removal.
Methods: A modified murine air pouch model with an inline filter removed excipients prior to insulin infusion/injection. Protein analysis by circular dichroism (CD) measured protein stability upon excipient removal. A separate analysis determined cytotoxicity for insulin fibrils in cell and tissue. These studies were also extended into a porcine model.
Results: Excipient removal significantly reduced the inflammatory response in vivo. However, this resulted in a loss of insulin oligomeric state. In vitro and in vivo studies demonstrated toxicity of excipients (in vitro and in vivo) and fibrils (in vivo) (Figures 1A-D).
Conclusions: These studies demonstrate that insulin excipients result in cell and tissue toxicity. Complete removal of these excipients alters protein stability. Since inflammation is minimized with removal of excipients, current studies are directed at optimizing the infusion parameters and excipient concentrations.

Disclosure
B. Lewis: None. A. Mulka: None. C. Kesserwan: None. D. Kreutzer: Other Relationship; Self; Abbott Laboratories, cell and molecualar tissue enginnering (cmte). U. Klueh: Research Support; Self; Abbott. Other Relationship; Self; Cell and Molecular Tissue Engineering, LLC.

Funding
The Leona M. and Harry B. Helmsley Charitable Trust
99-OR: An Inflection Point (IP) of C-Peptide (C-P) Decline during Progression to Type 1 Diabetes (T1D)
Authors: ISMAIL HEBA M. , SKYLER JAY S. , SOSENKO JAY , PALMER JERRY P. , EVANS-MOLINA CARMELLA , DIMEGLIO LINDA , REDONDO MARIA J. , STECK ANDREA , ATKINSON MARK A. , HEROLD KEVAN C. , NATHAN BRANDON M. 
Published: June 2020

Evidence suggests the presence of an IP for accelerated β-cell loss during progression to T1D. Importantly, identification of an IP could guide subject selection for prevention trials. We used a 2-dimensional grid of area under the curve (AUC) glucose vs. AUC C-P to detect a C-P IP among Diabetes Prevention Trial-Type 1 (DPT-1; n=54) and TrialNet (TN; n=59) autoantibody positive (Ab+) participants. All analyzed were required to have OGTTs at baseline and every 6 months, then 2.0, 1.5, 1.0 and 0.5 yrs before diagnosis. In DPT-1, an IP was evident 1.5 yrs from diagnosis (Figure) (AUC C-P change from baseline to 1.5 yrs: 0.22±0.60 ng/ml, p=0.006; from 1.5 to 0.5 yrs: -0.42±1.23 ng/ml, p=0.026). In TN, a 1.5 yr IP was also evident (from baseline to 1.5 yrs: 0.18±0.95 ng/ml, p=0.184; from 1.5 to 0.5 yrs: -0.53±1.57 ng/ml, p=0.015), despite an older TN cohort (14.9±12.1 vs. 10.5±6.8 yrs, p=0.023) with higher AUC C-P (5.0±1.9 vs. 3.3±1.6 ng/ml, p&lt;0.001). There was no IP in non-progressors.
In summary, an IP occurred 1.5 yrs before diagnosis when C-P began to decline as glucose continued to increase in DPT-1 and TN, suggesting that a 1.5 yr IP of C-P decline is consistent among Ab+ populations. These findings emphasize the importance of identifying at risk individuals as potential participants in prevention trials prior to the IP, when the loss of insulin secretion becomes more severe.

Disclosure
H.M. Ismail: None. J.S. Skyler: Advisory Panel; Self; Abvance Therapeutics, ADOCIA, Avotres, Boehringer Ingelheim Pharmaceuticals, Inc., Dance Biopharm Holdings, Inc., Immunomolecular Therapeutics, Intrexon, Oramed Pharmaceuticals, Orgenesis Inc., Sanofi, Tolerion, Inc., Viacyte, Inc. Board Member; Self; Applied Therapeutics, Dexcom, Inc., Intarcia Therapeutics. Consultant; Self; Novo Nordisk A/S. Research Support; Self; Tolerion, Inc. Stock/Shareholder; Self; Applied Therapeutics, Dexcom, Inc., Intarcia Therapeutics. J. Sosenko: None. J.P. Palmer: None. C. Evans-Molina: Consultant; Self; Bristol-Myers Squibb. L. DiMeglio: None. M.J. Redondo: None. A. Steck: None. M.A. Atkinson: None. K.C. Herold: Consultant; Self; Provention Bio, Inc. B.M. Nathan: None.

Funding
National Institutes of Health
994-P: Clinical Study of a New Extended Wear Infusion Set
Authors: ILANY JACOB , COHEN OHAD , KONVALINA NOA , ZHANG GINA , CHATTARAJ SARNATH 
Published: June 2020

Objective: Current real-time continuous glucose monitoring (CGM) sensors are approved for 7-14 days of wear, whereas insulin infusion sets are indicated for 2-3 days of wear. Development of a closed-loop control system with the same duration of wear for its CGM and insulin infusion consumables necessitates an infusion set with greater longevity. This study assessed the safety and performance of a newly designed Extended Wear Infusion Set (EWIS) for up to 7 days.
Method: A single-center feasibility study targeted the recruitment of 26 adult subjects (between 22 and 75 years of age) This was a 1-center, prospective, open label one arm study, with each subject being asked to wear 4 trial devices until the infusion set failed or 7-day use was reached.
Result: There were twenty-one participants of whom 20 completed the study, resulting in 82 insertions and 78 wear counts. At 7 days of wear, the overall failure rate for the EWIS was 19.5%, which was comparable to that after 3-day use for a 3-day infusion set (∼23%) (MiniMed™ Quick-set), as previously reported. (Patel et al. Diabetes Technol Ther. 2014; 16:15-19). Over time, EWIS use for 7 days did not significantly increase hyperglycemia (mean SG value Day 3: 150 ± 56 mg/dL; Day 6: 160 ± 50 mg/dL; target &lt; 250 mg/dL) or total daily insulin requirements (TDI at Day 1: 41±17 U/Day; Day 3: 40±17 U/Day; Day 7: 43 ±20 U/Day) There were no events of infusion set blockage or diabetic ketoacidosis during the study.
Conclusion: The performance of the EWIS across 7 days of use was equivalent to the performance reported for a 3-day infusion set during 3 days of use. Safety outcomes during EWIS use were acceptable for the intended subcutaneous insulin infusion by an external pump for 7 days.

Disclosure
J. Ilany: Research Support; Self; Medtronic. O. Cohen: Employee; Self; Medtronic. N. Konvalina: None. G. Zhang: None. S. Chattaraj: Employee; Self; Medtronic.

Funding
Medtronic
PENGARUH PUPUK HAYATI DAN BAHAN ORGANIK TERHADAP POPULASI DAN BIOMASSA CACING TANAH PADA PERTANAMAN BAWANG MERAH (Allium ascalonicum L) DI KECAMATAN MERBAU MARATAM KABUPATEN LAMPUNG SELATAN
Authors: Arofi Annove Kurnia , Yusnaini Sri , Hendarto Kus , Arif Mas Achmad Syamsul 
Published: June 2020

This study aimed to determine the effect of biofertilizer, organic matter and the interaction between biofertilizer and organic matter on population, biomass of earthworm and shallot production. This experiment was conducted in Merbau Mataram, South Lampung Regency on September – December 2017, designed by using Randomize Block Design (RBD) with two factors, i.e. : Biofertilizer application consists of biofertilizer and non biofertilizer and organic matter application consists of chicken manure, cow manure, oyster mushroom baglog and straw compost. Analysis of variance (anova) was carried out using a significance level of 0,05 after verifying the additivity (Tukey’s test) and homogeneity of variance (Bartlett’s test) of the data. When a significant effect was revealed in the anova, the mean separations among treatments were obtained by least significant difference (LSD 0.05). The results showed that application of biofertilizer (Bio max grow) increased earthworm population in 37 days after planting at 10 – 20 cm depth and 70 days after planting at 0 – 10 and 10 – 20 cm depth, biofertilizer application also affected earthworm biomass and shallot production in 70 days after planting. Oyster mushroom application gave the best effect compared to the other organic matter on population and biomass of earthworm and shallot production.
Effect of serum total protein concentration on early-life health and growth of dairy calves
Authors: Cortese Victor S. , Kirkpatrick Mark A. , Short Thomas H. , Voortman Brian 
Published: June 2020

Abstract

OBJECTIVE
To assess the effect of serum total protein (STP) concentration on the early-life health and growth of dairy calves.

ANIMALS
39,619 neonatal Holstein, Jersey, and crossbred calves from 15 dairy operations.

PROCEDURES
Calves arrived at a single calf-raising facility at approximately 2 days old. Each calf was weighed at facility arrival, and a blood sample was obtained the next day for determination of STP concentration by refractometry. All calves were managed in a standard manner, and health events were recorded for 120 days. A subset of 3,214 calves was weighed at 120 days old, and the average daily gain (ADG) was calculated. Linear mixed models were used to assess the effect of STP concentration on specific health events.

RESULTS
STP concentration was associated with the incidences of death, diarrhea, pneumonia, and whether a calf received IV fluid therapy. In general, the incidence of adverse health events decreased as STP concentration increased to 6.0 g/dL, plateaued at STP concentrations between 6.0 and 8.5 g/dL, and increased at STP concentrations > 8.5 g/dL. Although STP concentration was not associated with ADG, the ADG for Holsteins increased as STP concentration increased to 8.5 g/dL and then decreased at STP concentrations > 8.5 g/dL.

CONCLUSIONS AND CLINICAL RELEVANCE
Results suggested that, for neonatal dairy calves, an STP concentration between 6.0 and 8.5 g/dL was optimal for health and growth, and calves with an STP concentration < 5.0 or > 8.5 g/dL should be considered at high risk for adverse health events.
PENGARUH PERBANDINGAN TERIGU DAN BEKATUL BERAS MERAH TERHADAP KARAKTERISTIK MIE KERING
Authors: Budihartini Ni Komang Sri , Permana I Dewa Gede Mayun , Ina Putu Timur 
Published: June 2020

The purpose of study were to find the optimum ratio of wheat flour with red rice bran to produce the best characteristics of dry noodle. The Completely Randomized Design was used in the research with treatment that is the ratio of flour with red rice bran which consist of 6 levels: 100%:0%; 95%:5%; 90%:10%; 85%:15%; 80%:20%; 75%:25%. The treatment was repeated 3 times to obtain 18 units of experiment. The data obtained were analyzed by variance and if the treatment had an effect on the observed variable then continued with Duncan Multiple Range Test (DMRT) test. The ratio of flour to red rice bran significantly influenced moisture, ash , fat, protein, carbohydrate, curde fiber content, inhibitor concentration (IC50), water absorption, color (scoring test), flavor (hedonic test), texture (hedonic test and scoring), taste (hedonic test) as well as overall acceptance (hedonic test) dry noodle.The ratio of wheat flour and red rice bran flour (80%:20%) produces dry noodle with the best characteristics namely: 10.67% moisture content, ash content 2.91%, 1.09% fat content, 13.52% protein content, 71.80 % carbohydrate content, 4.15% crude fiber content, IC50 149.35 mg/ml, water absorption 223.23%, dark red color and rather liked color, rather liked flavor, elastic and rather liked texture, rather liked taste and rather liked overall acceptability.